Dove's Real Beauty playbook collides with the Ozempic era
Two decades after Dove rewrote beauty marketing around body positivity, GLP-1 drugs are pharmaceutically restoring thinness as aspiration. Personal-care marketers now face a strategic split: defend inclusivity equity built since 2004, or follow consumers reshaping their bodies via Ozempic, Wegovy and Mounjaro.
What happened
Dove's two-decade-old Real Beauty body-positive positioning faces cultural pressure as GLP-1 weight-loss drugs like Ozempic normalise thinness again, leaving
Key facts
- 2004
Why this matters
Scout adjacent assets—wellness, skin-tightening, post-weight-loss skincare brands—that let a Dove-aligned portfolio monetize the GLP-1 body transition without retiring two decades of inclusivity equity on the flagship.